Breast Implant-Associated Anaplastic Large Cell Lymphoma (BIA-ALCL) and the Textured Breast Implant Crisis

Groth, Anne Karoline; Graf, Ruth

doi:10.1007/s00266-019-01521-3

Cited by 82 publications

(56 citation statements)

References 51 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…BIA-ALCL has been widely discussed since the reports of the first cases related to textured silicone implants. However, the trigger point of this pathology is still unknown [1] . Since we started a research protocol in our institution to search for breast implant complications, we observed an increasing number of SIGBIC cases.…”

Section: Discussionmentioning

confidence: 99%

Synchronous breast implant associated anaplastic large cell lymphoma (BIA-ALCL) and silicone induced granuloma of breast implant capsule (SIGBIC): What to learn

Fleury

2020

Radiology Case Reports

View full text Add to dashboard Cite

We recently described silicone induced granuloma of breast implant capsule (SIGBIC) as an implant capsule illness related to intact silicone breast implants. The precursor to SIGBIC development is gel bleeding/shedding from the implant shell/interior content. Currently, although the literature widely discussed the pathogenesis of breast implant-associated anaplastic large cell lymphoma (BIA-ALCL), the trigger point for its development is still a black-box. In this case report, we report a 46-year-old woman with SIGBIC diagnosis in her right breast and BIA-ALCL in her left breast, diagnosed with ultrasound and breast magnetic resonance. Microscopy confirmed silicone bleeding from the implant surface/ content. The imaging findings reported that SIGBIC and BIA-ALCL were similar; however, BIA-ALCL had an intracapsular collection.

show abstract

Section: Discussionmentioning

confidence: 99%

Synchronous breast implant associated anaplastic large cell lymphoma (BIA-ALCL) and silicone induced granuloma of breast implant capsule (SIGBIC): What to learn

Fleury

2020

Radiology Case Reports

View full text Add to dashboard Cite

show abstract

“…Catalysts, vulcanizing agents, and non-siloxane fillers may also be present in varying proportions [55,57]. The texture of implants has also attracted some debate, although again focus may be better made towards the chemistry of these foreign bodies [97,98]. With such potential variety for chemical concoction, is it appropriate that all silicones should be treated equally or clustered as an entity when discussing ASIA or immune reactivity otherwise?…”

Section: Autoimmune/inflammatory Syndrome Induced By Adjuvantsmentioning

confidence: 99%

Mast Cell Biology and Linkages for Non-clonal Mast Cell Activation and Autoimmune/Inflammatory Syndrome Induced by Adjuvants

Cimolai

2020

SN Compr. Clin. Med.

View full text Add to dashboard Cite

Non-clonal mast cell activation disorder (syndrome) (NC-MCAD) and autoimmune/inflammatory syndrome induced by adjuvants (ASIA) are complex syndromic and spectral clinical entities which have contemporaneously garnered considerable attention and rightfully so. NC-MCAD presents with a predominantly allergic profile, and causative clinical variables may or may not be identified. Manifest NC-MCAD illnesses can be complex and involve several organ systems. Such diversity may be in part explained by the ubiquity and plasticity of the mast cell. ASIA, due to its broad definition, continues to expand as a clinical entity, especially with the greater recognition of what might constitute adjuvancy. Such diversity has the potential to overly stretch the boundaries for scientific investigation. For both NC-MCAD and ASIA, the inciting molecular mechanisms require elucidation. Future research would benefit from greater precision for clinical diagnosis and risk factor identification, and the latter would be potentially facilitated by the discovery of reliable laboratory markers. Some patients with ASIA may present with clinical features that may be identified as NC-MCAD. This review examines the potential spectral nexus of NC-MCAD and ASIA and considers the role of the mast cell in such a possible interface.

show abstract

“…There are 35 million patients with implants in the world, and at the present moment, 573 cases of BIA-ALCL have been reported. 14 – 17 Systematic review of the literature via PubMed covering cases series, modes of presentation, cytological, histological and immunohistochemical features, and disease outcome, since 1997, shows that 518 cases throughout 25 countries have been registered on the American Society of Plastic Surgeons PROFILE registry, with an estimated risk for women with an implant of 1–3 per million per year. The neoplastic cells are highly atypical, consistently strongly positive for CD30, with 43%–90% also positive for EMA, and all are ALK-negative.…”

Section: Is the Use Of The Breast Implant Capsule For Reconstruction mentioning

confidence: 99%

Interpositional Arthroplasty Using Mammary Capsule for Finger Joints: A Novel Technique

Mesa

López

Mesa

2020

Plastic and Reconstructive Surgery - Global Open

View full text Add to dashboard Cite

Breast Implant-Associated Anaplastic Large Cell Lymphoma (BIA-ALCL) and the Textured Breast Implant Crisis

Cited by 82 publications

References 51 publications

Synchronous breast implant associated anaplastic large cell lymphoma (BIA-ALCL) and silicone induced granuloma of breast implant capsule (SIGBIC): What to learn

Synchronous breast implant associated anaplastic large cell lymphoma (BIA-ALCL) and silicone induced granuloma of breast implant capsule (SIGBIC): What to learn

Mast Cell Biology and Linkages for Non-clonal Mast Cell Activation and Autoimmune/Inflammatory Syndrome Induced by Adjuvants

Interpositional Arthroplasty Using Mammary Capsule for Finger Joints: A Novel Technique

Contact Info

Product

Resources

About